3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
59
Nivolumab
34
Cyclophosphamide
21
fludarabine
15
Paclitaxel
12
Ipilimumab
12
atezolizumab
11
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
Carboplatin
10
Docetaxel
9
Cisplatin
9
Gemcitabine
8
Biopsy
8
durvalumab
7
aldesleukin
7
Radiosurgery
7
Interleukin-2
7
Bevacizumab
7
cemiplimab
6
Pemetrexed
6
fludarabine phosphate
5
avelumab
5
Radiotherapy
5
Drug Therapy
5
spartalizumab
4
epacadostat
4
enzalutamide
4
Taxes
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Desflurane
×
Gastrointestinal
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled